Vestcor Inc Sells 20,238 Shares of Hims & Hers Health, Inc. $HIMS

Vestcor Inc decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 48.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,955 shares of the company’s stock after selling 20,238 shares during the quarter. Vestcor Inc’s holdings in Hims & Hers Health were worth $713,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S increased its stake in Hims & Hers Health by 40.9% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 151,041 shares of the company’s stock valued at $4,904,000 after buying an additional 43,826 shares during the last quarter. Vise Technologies Inc. increased its stake in Hims & Hers Health by 186.8% in the 4th quarter. Vise Technologies Inc. now owns 12,976 shares of the company’s stock valued at $421,000 after buying an additional 8,452 shares during the last quarter. Cibc World Market Inc. increased its stake in Hims & Hers Health by 171.3% in the 4th quarter. Cibc World Market Inc. now owns 15,666 shares of the company’s stock valued at $509,000 after buying an additional 9,892 shares during the last quarter. Intellectus Partners LLC increased its stake in Hims & Hers Health by 5.4% in the 4th quarter. Intellectus Partners LLC now owns 72,110 shares of the company’s stock valued at $2,341,000 after buying an additional 3,699 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Hims & Hers Health by 3.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,380,357 shares of the company’s stock valued at $44,820,000 after buying an additional 40,655 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the transaction, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $6,216,232.56. The trade was a 2.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Finally, Bank of America decreased their price objective on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research note on Tuesday, May 26th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.70.

Hims & Hers Health Trading Up 3.4%

Shares of HIMS stock opened at $27.08 on Tuesday. The company has a 50 day moving average of $24.73 and a 200-day moving average of $26.96. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market cap of $6.27 billion, a P/E ratio of -300.88, a PEG ratio of 49.14 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the previous year, the business earned $0.20 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.